Micro RNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia

Blood

Volumn 124, Issue 4, 2014, Pages 546-554

  Cui, Bing ^a   Chen, Liguang ^a   Zhang, Suping ^a   Mraz, Marek ^a,b   Fecteau, Jessie F ^a   Yu, Jian ^a   Ghia, Emanuela M ^a   Zhang, Ling ^a   Bao, Lei ^a   Rassenti, Laura Z ^a   Messer, Karen ^a   Calin, George A ^c   Croce, Carlo M ^c   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MASARYK UNIVERSITY   (Czech Republic)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD40 LIGAND; CD5 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MICRORNA 155; PROTEIN KINASE ZAP 70; CALCIUM; INOSITOL 1,4,5 TRISPHOSPHATE 5 PHOSPHATASE; INOSITOL-1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; MICRORNA; MIRN155 MICRORNA, HUMAN; PHOSPHATASE; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; LEUKEMIA CELL; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MICROENVIRONMENT; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD5; BLOTTING, WESTERN; CALCIUM; CD40 LIGAND; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICRORNAS; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84904887947     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559690     Document Type: Article

References (46)

1. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev. 2007;7(2):102-108. (Pubitemid 350116720)
2. Kil LP, Yuvaraj S, Langerak AW, Hendriks RW. The role of B cell receptor stimulation in CLL pathogenesis. Curr Pharm Des. 2012;18(23): 3335-3355.
3. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-4614. (Pubitemid 35429705)
4. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111(5):2685-2692.
5. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
6. Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847-859. (Pubitemid 350258623)
7. Koralov SB, Muljo SA, Galler GR, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008;132(5): 860-874. (Pubitemid 351312808)
8. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801. (Pubitemid 41549891)
9. Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 2009;50(3):506-509.
10. Mraz M, Dolezalova D, Plevova K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012;119(9):2110-2113.
11. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissuespecific microRNAs from mouse. Curr Biol. 2002; 12(9):735-739.
12. Tam W, Ben-Yehuda D, Hayward WS. bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol. 1997;17(3):1490-1502. (Pubitemid 27097379)
13. Leng RX, Pan HF, Qin WZ, Chen GM, Ye DQ. Role of microRNA-155 in autoimmunity. Cytokine Growth Factor Rev. 2011;22(3):141-147.
14. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005; 102(10):3627-3632. (Pubitemid 40354662)
15. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-249. (Pubitemid 41404155)
16. Zhang Y, Roccaro AM, Rombaoa C, et al. LNA-mediated anti-miR-155 silencing in lowgrade B-cell lymphomas. Blood. 2012;120(8): 1678-1686.
17. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(32):11755-11760. (Pubitemid 39095368)
18. Marton S, Garcia MR, Robello C, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 2008;22(2):330-338. (Pubitemid 351250538)
19. Wang M, Tan LP, Dijkstra MK, et al. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR- 150 and high BIC/miR-155 expression. J Pathol. 2008;215(1):13-20. (Pubitemid 351619871)
20. Nana-Sinkam SP, Croce CM. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet. 2010; 203(2):127-133.
21. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006; 103(18):7024-7029.
22. Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009;114(18): 3872-3879.
23. Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116(6): 945-952.
24. Vargova K, Curik N, Burda P, et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011; 117(14):3816-3825.
25. Zhu DX, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012;33(7):1294-1301.
26. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 2009; 106(17):7113-7118.
27. Pedersen IM, Otero D, Kao E, et al. OncomiR- 155 targets SHIP1 to promote TNFalphadependent growth of B cell lymphomas. EMBO Mol Med. 2009;1(5):288-295.
28. Zolnierowicz S, Bollen M. Protein phosphorylation and protein phosphatases. De Panne, Belgium, September 19-24, 1999. EMBO J. 2000;19(4): 483-488. (Pubitemid 30093720)
29. Nakamura K, Brauweiler A, Cambier JC. Effects of Src homology domain 2 (SH2)-containing inositol phosphatase (SHIP), SH2-containing phosphotyrosine phosphatase (SHP)-1, and SHP-2 SH2 decoy proteins on Fc gamma RIIB1-effector interactions and inhibitory functions. J Immunol. 2000;164(2):631-638. (Pubitemid 30043682)
30. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
31. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901. (Pubitemid 39096916)
32. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15): 2529-2537.
33. Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011; 17(11-12):1374-1382.
34. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002;32(5): 1403-1413. (Pubitemid 34546268)
35. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106(3):1012- 1020. (Pubitemid 41076448)
36. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med. 2013;19:115-123.
37. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122(11): 1891-1899.
38. Tableman M, Kim JS. Survival Analysis Using S: Analysis of Time-to-Event Data. Boca Raton, FL: Chapman & Hall/CRC; 2004.
39. Lössner C, Meier J, Warnken U, et al. Quantitative proteomics identify novel miR-155 target proteins. PLoS ONE. 2011;6(7):e22146.
40. Chang CC, Zhang QY, Liu Z, Clynes RA, Suciu-Foca N, Vlad G. Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells. J Immunol. 2012;188(7): 3042-3052.
41. di Iasio MG, Norcio A, Melloni E, Zauli G. SOCS1 is significantly up-regulated in Nutlin-3-treated p53(wild-type) B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs. 2012;30(6): 2403-2406.
42. Neilsen PM, Noll JE, Mattiske S, et al. Mutant p53 drives invasion in breast tumors through upregulation of miR-155. Oncogene. 2013;32(24): 2992-3000.
43. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
44. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2): 703-710. (Pubitemid 46105972)
45. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA. 2004; 101(21):8108-8113. (Pubitemid 38698062)
46. Kluiver J, van den Berg A, de Jong D, et al. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene. 2007; 26(26):3769-3776. (Pubitemid 46878126)